Michael Rugnetta has an article at Science Progress suggesting that NIH's genetic-based warfarin study will help determine the potential for personalized medicine. "Certainly the outcome could have enormous implications for personalized medicine, a new medical field where the results of genetic tests or other biomarker assessments are used to tailor drugs and treatments to individual patients," he writes. "Pharmacogemomics-based treatments ... need to pass the practicality test if biomedical innovation is to make a constructive contribution to a larger system-based healthcare infrastructure."
PGx in a Microcosm
Mar 04, 2009